Literature DB >> 31408090

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.

N Chaput, P Lepage, C Coutzac, E Soularue, K Le Roux, C Monot, L Boselli, E Routier, L Cassard, M Collins, T Vaysse, L Marthey, A Eggermont, V Asvatourian, E Lanoy, C Mateus, C Robert, F Carbonnel.   

Abstract

Entities:  

Year:  2019        PMID： 31408090     DOI： 10.1093/annonc/mdz224

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  18 in total

1.  T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.

Authors:  Alexander X Lozano; Aadel A Chaudhuri; Aishwarya Nene; Aaron M Newman; Antonietta Bacchiocchi; Noah Earland; Matthew D Vesely; Abul Usmani; Brandon E Turner; Chloé B Steen; Bogdan A Luca; Ti Badri; Gunsagar S Gulati; Milad R Vahid; Farnaz Khameneh; Peter K Harris; David Y Chen; Kavita Dhodapkar; Mario Sznol; Ruth Halaban
Journal:  Nat Med       Date:  2022-01-13       Impact factor: 87.241

Review 2.  Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light.

Authors:  Jie Zhang; Kanghui Wu; Cuicui Shi; Guangming Li
Journal:  Curr Treat Options Oncol       Date:  2022-10-24

Review 3.  Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.

Authors:  Brendan L Mangan; Renee K McAlister; Justin M Balko; Douglas B Johnson; Javid J Moslehi; Andrew Gibson; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2020-07-17       Impact factor: 4.335

4.  Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.

Authors:  Preeti Kanikarla Marie; Cara Haymaker; Jean-Nicolas Vauthey; Michael J Overman; Edwin Roger Parra; Young Uk Kim; Rossana Lazcano; Swati Gite; Daniele Lorenzini; Ignacio I Wistuba; Rebecca S Slack Tidwell; Xiaofei Song; Wai Chin Foo; Dipen M Maru; Yun Shin Chun; Andy Futreal; Bryan Kee; David Menter; Luisa Solis; Ching-Wei Tzeng; Christine Parseghian; Kanwal Raghav; Van Morris; Chia-Chi Chang; Robert Jenq; Alda Tam; Chantale Bernatchez; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2021-04-02       Impact factor: 12.531

Review 5.  Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.

Authors:  R Zou; Y Wang; S Cui; F Ye; X Zhang; M Wang
Journal:  Clin Transl Oncol       Date:  2021-05-17       Impact factor: 3.405

Review 6.  Checkpoint Inhibitors and Induction of Celiac Disease-like Condition.

Authors:  Aaron Lerner; Carina Benzvi
Journal:  Biomedicines       Date:  2022-03-04

7.  Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations.

Authors:  Hannah R Wardill; Raymond J Chan; Alexandre Chan; Dorothy Keefe; Samuel P Costello; Nicolas H Hart
Journal:  Support Care Cancer       Date:  2022-03-10       Impact factor: 3.359

Review 8.  Mechanisms of immune activation and regulation: lessons from melanoma.

Authors:  Shelly Kalaora; Adi Nagler; Jennifer A Wargo; Yardena Samuels
Journal:  Nat Rev Cancer       Date:  2022-02-01       Impact factor: 69.800

Review 9.  Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers.

Authors:  Vito Amodio; Gianluca Mauri; Nicole M Reilly; Andrea Sartore-Bianchi; Salvatore Siena; Alberto Bardelli; Giovanni Germano
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

10.  Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.

Authors:  Bao-Dong Qin; Xiao-Dong Jiao; Xin-Cheng Zhou; Bin Shi; Jian Wang; Ke Liu; Ying Wu; Yan Ling; Yuan-Sheng Zang
Journal:  Oncoimmunology       Date:  2021-07-21       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.